65,536 routable5 ASes
/16 subnet
160.62.0.0/16
Where this subnet is, who announces it, and what our databases hold in it. Below, every /24 inside it; open one for its addresses.
65,536
routable addresses
65,536
geolocated
5
countries
5
announcing ASes
16
announced prefixes
22
anonymous addresses
Where it is
Addresses IP Geolocation places in each country, as a share of those it places.
- Switzerland62,720 · 95.70%
- United States1,536 · 2.34%
- Germany512 · 0.78%
- Singapore512 · 0.78%
- Russia256 · 0.39%
Who announces it
Each /24 counted for the AS announcing most of it, as a share of the routable addresses.
What the databases see
Addresses each address-keyed database holds in this block, as a share of its routable addresses. Counts overlap: one address can be in several.
- VPN IP210.03%
- 0.00%
- None here
- None here
- None here
- None here
- None here
- None here
- None here
- None here
- None here
- None here
- 0.01%
Announced prefixes
Every prefix inside this block that BGP Route saw announced, with its origin and RPKI status.
| PREFIX | ORIGIN | COUNTRY | RPKI | PEERS | FIRST SEEN |
|---|---|---|---|---|---|
| 160.62.1.0/24 | AS25031Novartis AG | Switzerland | valid | 17 | 2026-10-02 |
| 160.62.2.0/24 | AS25031Novartis AG | Switzerland | valid | 17 | 2026-10-02 |
| 160.62.3.0/24 | AS25031Novartis AG | Switzerland | valid | 17 | 2026-10-02 |
| 160.62.4.0/24 | AS25031Novartis AG | Switzerland | valid | 17 | 2026-10-02 |
| 160.62.5.0/24 | AS25031Novartis AG | Switzerland | valid | 17 | 2026-10-02 |
| 160.62.6.0/24 | AS25031Novartis AG | Switzerland | valid | 17 | 2026-10-02 |
| 160.62.7.0/24 | AS25031Novartis AG | Switzerland | valid | 17 | 2026-10-02 |
| 160.62.9.0/24 | AS200471Novartis AG | United States | valid | 17 | 2026-10-02 |
| 160.62.12.0/24 | AS47444Novartis AG | Singapore | valid | 17 | 2026-10-02 |
| 160.62.13.0/24 | AS47444Novartis AG | Singapore | valid | 17 | 2026-10-02 |
| 160.62.14.0/24 | AS26478Novartis Pharmaceuticals | United States | valid | 17 | 2026-10-02 |
| 160.62.15.0/24 | AS26478Novartis Pharmaceuticals | United States | valid | 17 | 2026-10-02 |
| 160.62.21.0/24 | AS200471Novartis AG | United States | valid | 17 | 2026-10-02 |
| 160.62.22.0/24 | AS6095Novartis Institutes for BioMedical Research, Inc. | Germany | valid | 17 | 2026-10-02 |
| 160.62.23.0/24 | AS6095Novartis Institutes for BioMedical Research, Inc. | Germany | valid | 17 | 2026-10-02 |
| 160.62.140.0/23 | AS26478Novartis Pharmaceuticals | United States | valid | 17 | 2026-10-02 |
Every /24 inside it
00 · Evaluate
Test the real build first.
An evaluation license puts a full current build in your hands — every row, every column, no sampling — so you can measure it against your own traffic before anyone talks about terms.
01 · License
Then license what you use.
Standard, for detection and decisions inside your own product and operations.
Redistribution, when the data ships onward inside what you sell — priced by scope, not by seat.
Annual terms, a named contact, and flexible payment terms — monthly, quarterly or yearly.